Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Vercirnon

HY-15724

(GSK-1605786; CCX282-B)

Vercirnon

Vercirnon Chemical Structure

Vercirnon is a highly potent antagonist of CCR9, which has been implicated in the aetiology of inflammatory bowel diseases such as Crohn's disease.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $385 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €377 In-stock
5 mg €343 In-stock
10 mg €490 In-stock
50 mg €1470 In-stock
100 mg €2058 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Vercirnon
Cat. No.: HY-15724

Vercirnon Data Sheet

  • Pdf Version Network Version

    DataSheet

Related Compound Libraries

Biological Activity of Vercirnon

Vercirnon is a highly potent antagonist of CCR9, which has been implicated in the aetiology of inflammatory bowel diseases such as Crohn's disease.
IC50 value: <7 nM (Molt-4 cells, CCR9 transfected cell, primary derived human T cells, and murine and rat thymocytes)
Target: CCR9
in vitro: CCX282-B inhibits CCR9 mediated chemotaxis to CCL25 (IC50 <7 nM), measured in the Molt-4 cells, CCR9 transfected cell lines, primary derived human T cells, and murine and rat thymocytes.[1] CCX282-B inhibits CCR9-mediated Ca2+mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively.. CCX282-B inhibits chemotaxis of primary CCR9-expressing cells to CCL25 with an IC50 of 6.8 nM. CCX282-B is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively. [2]
in vivo: CCX282-B also inhibits mouse and rat CCR9-mediated chemotaxis. Inhibition of CCR9 with CCX282-B results in normalization of Crohn's disease such as histopathology associated with the TNFΔARE mice. [2]

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 444.93 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C22H21ClN2O4S
CAS No 698394-73-9
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.2475 mL 11.2377 mL 22.4754 mL
5 mM 0.4495 mL 2.2475 mL 4.4951 mL
10 mM 0.2248 mL 1.1238 mL 2.2475 mL

References on Vercirnon

Inhibitor Kit

Related CCR Products

  • INCB3344

    INCB3344 is a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor; inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM).

  • Maraviroc

    Maraviroc (UK-427857; Selzentry; Celsentri) is a selective CCR5 antagonist (IC50= 6.4 nM); displays potent anti-HIV-1 activity.

  • MK-0812

    MK-0812 is a potent and selective CCR2 antagonist with low nM affinity for CCR2 on human monocytes.

  • PF-4136309

    INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist.

  • RS 504393

    RS 504393 is a selective CCR2 chemokine receptor antagonist (IC50 values are 98 nM and > 100 (mu)M for inhibition of human recombinant CCR2b and CCR1 receptors respectively).

  • Vicriviroc maleate

    Vicriviroc maleate(Sch-417690) is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1.